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Abstract
Purpose: Glucosamine (GlcN) supplements are promoted for medical reasons, for example, for patients with
arthritis and other joint-related diseases. Oral intake of GlcN is followed by uptake in the intestine, transport
in the circulation and thereafter delivery to chondrocytes. Here, it is postulated to have an effect on synthesis
and turnover of extracellular matrix constituents expressed by these cells. Following uptake in the intestine,
serum levels are transiently increased, and the endothelium is exposed to increased levels of GlcN.
We investigated the possible effects of GlcN on synthesis of proteoglycans (PGs), an important matrix
component, in primary human endothelial cells.
Methods: Primary human endothelial cells were cultured in vitro in medium with 5 mM glucose and 010 mM
GlcN. PGs were recovered and analysed by western blotting, or by SDS-PAGE, gel chromatography or ion-
exchange chromatography of 35S-PGs after 35S-sulphate labelling of the cells.
Results: The synthesis and secretion of 35S-PGs from cultured endothelial cells were reduced in a dose- and
time-dependent manner after exposure to GlcN. PGs are substituted with sulphated glycosaminoglycan
(GAG) chains, vital for PG function. The reduction in 35S-PGs was not related to an effect on GAG chain
length, number or sulphation, but rather to the total expression of PGs.
Conclusion: Exposure of endothelial cells to GlcN leads to a general decrease in 35S-PG synthesis. These
results suggest that exposure to high levels of GlcN can lead to decreased matrix synthesis, contrary to what
has been claimed by supporters of such supplements.
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U
se of glucosamine (GlcN) as a dietary supple-
ment for patients with arthritis has been highly
debated (1, 2). Articular cartilage is composed of
chondrocytes embedded in an extracellular matrix mainly
composed of collagens and proteoglycans (PGs) (3). In
arthritis, cartilage erosion is a prominent clinical feature.
GlcN supplements have been used with the intention to
increase the supply of the building blocks for PG biosyn-
thesis, to increase synthesis and to decrease degradation
of cartilage. However, it is highly controversial whether
dietary supply of GlcN and chondroitin is of any use in
this disease (4, 5). It is not documented that arthritis is in
any way related to lack of nutrients. The data provided so
far have not provided any documentation of molecular
mechanisms for a positive effect of GlcN on cartilage de
novo biosynthesis. Arthritis is an inflammatory disease,
and GlcN is also suggested to be beneficial for these
patients through anti-inflammatory effects (6).
Plasma levels of GlcN are normally very low, and GlcN
is synthesised from glucose in each cell. However, GlcN
can also be taken up by cells through glucose transporters.
GlcN is further converted to uridine diphosphate (UDP)-
N-Acetyl glucosamine (UDP-GlcNAc) and UDP-N-Acet-
ylgalactosamine (UDP-GalNAc), building blocks for the
glycosaminoglycan (GAG) side chains of PGs.
Articular cartilage does not have blood vessels, nerves or
lymphatics, and delivery of circulatory molecules is slow.
Intake of GlcN supplements is most likely not able to
increase the GlcN availability in cartilage to any great
extent. The endothelial cells, however, are lining cells of the
blood vessels and are regularly exposed to high levels of
GlcN after ingestion. Consequently, how endothelial cells
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respond to elevated levels of GlcN is a relevant nutritional
issue. For this reason, the aim of this study was to
investigate the effects of increased GlcN levels on primary
human endothelial cells (HUVEC). The results presented
here show that endothelial cells respond to increased GlcN
levels by decreasing the synthesis and secretion of PGs.
This is the opposite of what is hypothesised for chondro-
cytes to give therapeutic beneficial effects.
Materials and methods
Primary human endothelial cells
HUVEC were isolated from infant umbilical vein of
delivering mothers at Rikshospitalet University Hospital
(7). None of the mothers providing umbilical cords had
any pregnancy complications, and ethical approval for
the use of HUVEC was obtained from the Human
Research Ethics Committee.
The cells were established in MCDB 131 medium
(Sigma) containing 5 mM glucose and supplemented
with 7% heat inactivated foetal calf serum (FCS, Sigma),
basic fibroblast growth factor (1 ng/ml, R&D), epidermal
growth factor (10 ng/ml, R&D), hydrocortisone (1 mg/ml,
Sigma), gentamicin (50 mg/ml, GIBCO Invitrogen) and
fungizone (250 ng/ml, GIBCO Invitrogen). Cells were used
for experiments within three passages, and culture medium
was changed every 4872 h. For experiments, the cells were
exposed to GlcN (0.1, 1, 2, 5 or 10 mM), and medium with
physiologic glucose concentration (5 mM) was used as a
control in all experiments. If not otherwise mentio-
ned, each result presented is a representative of three
experiments on HUVEC from different donors.
Cell viability
The possible cytotoxic effects of GlcN were investigated
by measurement of lactate dehydrogenase (LDH) activity
released from damaged cells using the Cytotoxicity
Detection Kit (Roche) according to the manufacturer’s
instructions.
To determine the effects of GlcN on HUVEC prolifera-
tion and cell viability, the adherent cells were released by
trypsin treatment and counted in a haemocytometer
(Bürker, Germany) after the addition of 0.4% trypan
blue. Cells positive for trypan blue were categorised as
dead cells.
35S-macromolecules
De novo synthesised PGs are readily detected by metabolic
labelling of their highly sulphated GAG chains by the
addition of 35S-sulphate (Hartmann Analytic) to the
culturing medium. In order to increase labelling efficiency,
the medium was changed to sulphate-free RPMI 1640
medium (GIBCO Invitrogen) containing 5 mM glucose
and 5 mM L-glutamine (Sigma) and FCS reduced to 2%.
HUVEC were labelled with 0.10.2 mCi/ml 35S-sulphate
for 24 h. During this period, the cells were also exposed to
GlcN (D-()-GlcN hydrochloride, Sigma) of different
concentrations indicated in the individual experiments.
After complete labelling, the medium fractions were
harvested and centrifuged to remove cell debris. Cells
were carefully rinsed in ice cold phosphate buffered saline
(PBS) and solubilised in 4 M guanidine hydrochloride
with 2% Triton X-100 in 0.05 M sodium acetate buffer
pH 6.0. In order to isolate the macromolecules and
remove excess unincorporated 35S-sulphate, 1 ml of each
fraction was applied to 4 ml columns of Sephadex G-50
Fine (GE Healthcare) gel chromatography in 0.05 M
Tris-HCl pH 8.0 with 0.05 M NaCl. The first 1 ml eluate
was discarded, and the following 1.5 ml eluate, containing
the 35S-macromolecules, was collected. The amount of 35S-
macromolecules was determined by scintillation counting
of aliquots of the material before further analysis. Cell
fraction protein was determined using the Uptima BC
Assay Protein Quantification Kit (Interchim). Prior to
analysis by gel filtration, ion-exchange chromatography
and, in some cases, SDS-PAGE, the anionic 35S-PGs were
further purified from the 35S-macromolecules by diethy-
laminoethanol (DEAE) ion-exchange chromatography.
Samples were applied to individual DEAE-sephacel poly-
prep columns equilibrated in 0.15 M NaCl Tris-buffer
(0.05 M Tris-HCl pH 8.0), washed in 0.15 M NaCl Tris-
buffer and 0.3 M NaCl Tris-buffer before eluted in 2 M
NaCl Tris-buffer.
SDS-PAGE
35S-macromolecules from HUVEC were analysed by
SDS-PAGE on precast 420% gradient gels (BioRad).
14C-labelled rainbow standards (Amersham) were used for
molecular weight determinations. Samples were desalted
and concentrated using Microcon Centrifugal Filter
Devices (Millipore) and vacuum centrifugation and then
run on SDS-PAGE, either untreated or after degradation
of GAG chains. For degradation of 35S-chondroitin
sulphate (CS) and dermatan sulphate (DS), samples from
media (5,000 cpm per analysis) were incubated at 378C
overnight with 0.01 units of chondroitinase ABC (cABC,
E.C. 4.2.2.4, Sigma Aldrich) in 0.05 M Tris-HCl pH 8.0,
containing 0.05 M sodium acetate. In parallel samples,
heparan sulfate (HS) was depolymerised by HNO2
deamination at pH 1.5, cleaving the polysaccharide at N-
sulphated GlcN units as described (8). In some experi-
ments, aliquots were subjected to cABC treatment prior to
HNO2 treatment, in order to depolymerise both the HS
and the CS/DS-GAGs present.
Prior to loading, the samples were incubated at room
temperature for 15 min in sample buffer with 1% SDS and
mercaptoethanol as reducing agent. After complete elec-
trophoresis, the gels were treated with fixing solution
(isopropanol 25%, glacial acetic acid 10%), amplified
(Amersham), dried on an SGD 2000 slab gel dryer
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(Thermo Savant), subjected to autoradiography for 37
days in 708C using Amersham HyperfilmTM ECL (GE
Healthcare) and finally visualised using an AGFA Curix-
60 developer.
Western blotting
Confluent HUVEC were exposed to 1 mM GlcN for 24 h
in standard culturing MCDB medium with FCS reduced
to 2%. Medium fractions were harvested and centrifuged
to remove cell debris. Cells were rinsed in ice cold PBS
and solubilised in radioimmunoprecipitation Assay
(RIPA) buffer (50 mM Tris-HCl pH 7.5, 150 mM
NaCl, 1% Triton X-100, 1% SDS, 1% Na-deoxycholate,
10 mM ethylenediaminetetraacetic acid (EDTA), 10 mM
Na4PO2O7 and Complete Mini EDTA-free cocktail
tablet from Roche). 35S-PGs from all fractions were
purified by DEAE ion-exchange chromatography and
concentrated using Microcon Centrifugal Filter Devices
(Millipore) or vacuum centrifugation. HS and CS/DS-
GAGs in media collected from HUVEC in the presence
or absence of 1 mM GlcN were depolymerised using
cABC or HNO2 as described.
For determination of the presence of perlecan or decorin
in the different media, the samples obtained were sepa-
rated on SDS-PAGE and electroblotted to a polyvinyl
difluoride (PVDF) membrane (Millipore, USA) using the
CriterionTMgel system (BioRad). Primary antibodies
against rabbit anti-human perlecan, kindly provided by
prof. RV Iozzo (1:500 dilution), and goat anti-human
decorin (1:4,000, R&D systems) were used. The secondary
antibody used was HRP-linked donkey anti-rabbit IgG
(1:50,000, GE Healthcare) and rabbit anti-goat IgG
(1:1,000, R&D systems), respectively. The membranes
were developed using ECL western blotting detection
reagents (GE Healthcare) and finally exposed to film and
developed using the AGFA Curix-60 developer. For
molecular weight determination, standards were run
simultaneously in separate lanes (BioRad).
Gene expression analysis
RNA was isolated from HUVEC using the E.Z.N.A Total
RNA Kit 1 according to the manufacturer’s instructions
and reverse transcribed using the High Capacity RNA-to-
cDNA Kit (Applied Biosystems). Quantitative real-time
PCR (qRT-PCR) was performed on an ABI Prism 7900HT
(Applied Biosystems) using TaqMan Gene Expression
Master Mix and the predesigned TaqMan Gene Expres-
sion Assays with RPL30 as endogenous control (HSPG2,
perlecan, Hs00194179_m1, SRGN serglycin Hs01004
1559_m1, SDC4 syndecan-4 Hs00161617_m1, BGN bigly-
can Hs00156076_m1 and RPL30 60S ribosomal protein
L30 Hs00265497_m1). The relative mRNA levels for each
transcript were calculated using the DDCt method.
Macromolecular properties of 35S-PGs
Both secreted and cell-associated 35S-PGs were isolated by
G50 fine gel chromatography and DEAE ion-exchange
chromatography. The samples were separated according to
size on a Sepharose CL-4B column, either untreated or as
35S-CS/DSPGs after HNO2 treatment or
35S-HSPGs after
cABC treatment. The column was run in 0.05 M Tris-HCl
pH 8 with 0.2 M NaCl, and fractions of 400800 ml were
collected and analysed for radioactivity by scintillation
counting. The elution profiles were determined relative to
the elution of the V0 marker dextran blue (2,500 kDa) and
the Vt marker phenol red (0.36 kDa).
NaOH treatment leads to the release of intact
GAG chains from their core proteins by b-elimination.
35S-macromolecules from conditioned medium and cell
lysate were either left untreated or subjected to HS
depolymerisation by HNO2 treatment or CS/DS digestion
by cABC treatment. The resulting CS/DS and HSPGs were
subjected to alkali b-elimination for release of the intact
GAGs from their core proteins. Samples containing CS/
DS and/or HS GAGs were recovered by DEAE ion-
exchange chromatography and concentrated and desalted
on vivaspin ultrafiltration devices (molecular weight cut-
off 30 kDa, GE Healthcare). The samples were further
separated according to size on a Sepharose CL-6B column
run in 0.05 M Tris-HCl pH 8 with 0.2 M NaCl. Frac-
tions were collected and analysed for radioactivity by
scintillation counting. The elution profiles were deter-
mined relative to the elution of the V0 marker dextran blue
(2,500 kDa) and the Vt marker phenol red (0.36 kDa).
Anionic properties of 35S-PGs
35S-macromolecules recovered from medium were
subjected to cABC or HNO2 treatment. The resulting
35S-HSPGs or 35S-CS/DS PGs were isolated by DEAE ion-
exchange chromatography. After dilution or salt removal
on vivaspin ultrafiltration devices, the samples were
analysed by ion-exchange chromatography with a salt
gradient ranging from 0.15 to 2 M NaCl in 0.05 M Tris-
HCl pH 8. Aliquots of each fraction were subjected to
scintillation counting and determination of the elution
profile of the internal standard CS-6 (Sigma) by the 1,9
dimethyl methylene blue assay.
Statistical analysis
The data were analysed using GraphPad Prism 5.03.
A Wilcoxon’s matched-pairs signed rank test was run to
determine if there were differences in cpm. The different
GlcN concentrations were compared to 0 mM GlcN, and
the different time-points were compared to baseline (0 h).
Differences of p50.05 were considered significant.
Results
HUVEC were exposed to different concentrations of
GlcN ranging from 0.1 to 10 mM and labelled with
Glucosamine exposure on endothelial cells
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35S-sulphate for 24 h. Radiolabelled macromolecules were
recovered by gel chromatography. 35S-macromolecules in
HUVEC are almost exclusively comprised of 35S-PGs (9).
From Fig. 1a, it is evident that there is a dose-dependent
decrease in both the synthesis and release of 35S-PGs
from HUVEC after incubation with GlcN, suggesting
that both synthesis and secretion of 35S-PGs were redu-
ced by GlcN. The protein content was measured in para-
llel cell cultures, and there was no difference between the
different HUVEC cultures, irrespective of GlcN concen-
trations used. No cytotoxic effects of GlcN were found
using the LDH assay. In addition, cells were counted
after trypsin treatment for detachment of the cells. The
trypan blue exclusion test showed high viability and
correlation between cell number and protein content up
to GlcN concentrations of 1 mM. At concentrations
above 1 mM, cell number was slightly reduced. For this
reason, 1 mM GlcN was used in all further experiments.
HUVEC were then exposed to 1 mM GlcN for different
time periods, and the amount of 35S-PGs was determined
in the cell and medium fractions. A time-dependent
decrease in the amount of 35S-PGs was observed both in
the medium and in the cell fractions (Fig. 1b), supporting
that both synthesis and secretion were inhibited in
HUVEC cultured in the presence of GlcN.
These findings were further corroborated by analysing
the 35S-PGs by SDS-PAGE. The secreted 35S-PGs were
clearly separated into three populations of almost equal
intensity  one of high molecular weight (migrating at the
top of the gel), a second with an approximate molecular
weight of 220 kDa and a third species with a molecular
weight around 100 kDa (Fig. 2a, left panel). This is in
accordance with previous studies (10). The cell fraction, in
contrast, mainly contained the high molecular weight
component (Fig. 2a, right panel). In both fractions, the
amount of these 35S-PGs decreased when the cells were
exposed to increasing concentrations of GlcN. It is also
evident from Fig. 2a that there was no prominent
difference in PG sizes between PGs synthesised after
exposure to increasing concentrations of GlcN. From
these experiments, we conclude that treatment of HUVEC
with GlcN resulted in a general decrease in de novo 35S-PG
expression.
The decrease in PG expression could be the result of a
decreased expression of either CS/DS-chains or HS-
chains, the major PG species expressed by HUVEC (11).
To analyse this, medium samples from control and GlcN-
treated cells, containing equal amounts of cpm, were
purified by Sephadex G50 fine and DEAE ion-exchange
chromatography and subjected to SDS-PAGE after cABC
degradation of CS/DS or HNO2 degradation of HS. From
Fig. 2b, it is evident that the high molecular weight band on
top of the gel is HSPGs, as it is degraded with HNO2 (H),
both in medium from control and GlcN-treated cells. The
35S-PGs at molecular weights of approximately 220 kDa
and 100 kDa were both CS/DS PGs, as can be seen by their
susceptibility to cABC treatment (labelled C in both
panels). A combination of both the treatments (CH)
revealed that almost all the labelled material was
35S-HSPGs and 35S-CS/DS PGs. These results suggest
that GlcN treatment leads to a general decrease in 35S-PG
biosynthesis and does not have a unique effect on the
expression of neither CS nor HS-type GAG chains.
Each different HS and CS/DS band most likely contains
several different PGs. These different PGs might have
different functions and responses to GlcN. We have
demonstrated that the extracellular matrix PGs perlecan
and decorin are highly expressed in HUVEC (10). Western
blotting was performed on untreated, cABC treated and
HNO2-treated medium fractions with antibodies against
the CS/DS PG decorin and the HSPG perlecan. Both the
intact PGs and the core proteins of perlecan and decorin
(Fig. 2c) were detected in the medium fractions of control
and GlcN-treated HUVEC. The molecular weight of both
intact perlecan and perlecan core protein was above
250 kDa. The decorin core protein had a molecular weight
around 40 kDa, whereas intact decorin was found at
100 kDa after SDS-PAGE. Both PGs were expressed and











































































Fig. 1. (a) HUVEC were exposed to the indicated GlcN concentrations and metabolically labelled for 24 h. (b) Cells exposed to
1 mM GlcN for the indicated times were metabolically labelled for the last 24 h. All responses, both for medium (left) and cell
lysate (right), are given as the cpm/protein ratios expressed relative to the control (0 mM GlcN). The difference compared to
control (ctr) was tested, and differences of p50.05 were considered significant. *pB0.05, **pB0.01, ***pB0.001.
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secreted in both control and GlcN exposed HUVEC and
the HS and CS/DS substitution was not affected. Accord-
ingly, both control and GlcN-treated HUVEC express
both decorin and perlecan, supporting the notion that the
decrease in PG expression after GlcN treatment is a
general effect rather than a selective effect on particular
PGs. Furthermore, gene expression of basement mem-
brane PG perlecan, the small leucine-rich PG biglycan, the
cell surface PG syndecan-4 and the intracellular PG
serglycin was determined, and none of these were sig-
nificantly altered by GlcN treatment (Fig. 2d).
PGs are substituted with GAG chains of varying
numbers, length and identity. Through these chains, the
PGs interact with a wide range of partner molecules
including matrix molecules, cytokines, growth factors
and proteases. These chains are further modified by
sulphation at distinct positions. Both the specific sulpha-
tion pattern and the overall negative charge created can be
important for interaction with partner molecules. In
summary, these chains are crucial for the functions of the
PGs, and they can be modified by a changing environment.
Here, we explored if GlcN exposure could modulate the
structure of the GAG chains. First, the size distribution of
35S-PGs synthesised and secreted in the absence or
presence of GlcN was compared. 35S-PGs were purified
by ion-exchange chromatography and subjected to size
determination by Sepharose CL-4B gel chromatography.
Exposure to GlcN did not alter the size of neither the cell-
associated nor the secreted 35S-PGs, evident from Fig. 3a,
left and right panels, indicating no apparent effect on GAG
substitution.
However, the observed lack of effect on PG size could be
explained by simultaneous changes in GAG size and
number. To analyse this in further detail, the 35S-PGs
were subjected to alkali b-elimination. The resulting free
35S-GAGs were recovered by DEAE ion-exchange chro-
matography, and the effect of GlcN on the GAG chain size
distribution was determined by Sepharose CL-6B gel
chromatography. From Fig. 3b, it is evident that the overall
chain length was not affected by exposure to GlcN.
To explore the effect of GlcN on the 35S-GAG compo-
nents in further detail, 35S-PGs synthesised in the presence
or absence of GlcN were subjected to enzymatic CS/DS-
depolymerisation by cABC. The remaining 35S-HS were
released from the core protein by alkali b-elimination.
Fig. 2. (a) HUVEC were exposed to the indicated concentrations of GlcN and metabolically labelled for 24 h. The size and
relative expression of the 35S-PGs obtained from medium (left panel) and cell lysate (right panel) are visualised by subjection to
SDS-PAGE after protein standardisation. (b) HUVEC cultured in 5 mM glucose alone (ctr) or added 1 mM GlcN were
metabolically labelled for 24 h. Samples of isolated 35S-PGs were standardised to cpm and subjected to either cABC digestion
(C), HNO2 depolymerisation (H), a combination of the above (CH), or left untreated (U). The size and GAG substitution of
35S-PGs secreted from ctr and GlcN-stimulated cells are apparent after subjection to SDS-PAGE. (c). HUVEC were cultured in
5 mM glucose (ctr) or 1 mM GlcN for 24 h. The level of secretion and the GAG substitution of the PGs perlecan and decorin
are evident after subjection to western blotting. The isolated PGs were subjected to cABC digestion (C), HNO2
depolymerisation (H), a combination of the above (CH), or left untreated (U) and protein content were standardised.
The migration positions of high molecular weight markers are shown on the left side of the panel (in kDa). (d) Gene expres-
sion of perlecan (HSPG2), biglycan (BGN), serglycin (SRGN) and syndecan-4 (SDC4) in GlcN-treated cells was determined by
qRT-PCR. Values are expressed as the fold change in GlcN-treated cells relative to control cells.
Glucosamine exposure on endothelial cells
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These HS-GAG chains were recovered by DEAE ion-
exchange chromatography, and their relative length was
determined by Sepharose CL-6B gel chromatography, as
illustrated in Fig. 3c. The HS-GAG chain length was not
affected by exposure to GlcN, supporting the observation
in Fig. 2a.
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Fig. 3. Both control and GlcN (1 mM) treated cells were metabolically labelled with 35S-sulphate for 24 h. (a) The 35S- PGs were
isolated from the medium (left panel) and cell lysate (right panel) and analysed by Sepharose CL-4B chromatography. (b) The
35S-GAGs were obtained from the secreted (left panel) and cell-associated (right panel) PGs and analysed by Sepharose CL-6B
chromatography. (c) 35S-HS were obtained from the secreted (left panel) and cell-associated (right panel) PGs and analysed by
Sepharose CL-6B chromatography. These are one representative chromatogram out of three individual experiments. (d) The charge
distribution of secreted 35S-HSPGs (left panel) or 35S-CSPGs (right panel) were determined by DEAE ion-exchange chroma-
tography with a salt gradient ranging from 0.15 to 2.0 M NaCl. The peak fraction of the internal standard CS-6 is indicated by the
dotted line. These results are based on one individual experiment. All responses, given in cpm, are scaled for convenience.
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The fact that neither PG size nor GAG chain length was
affected by GlcN treatment suggests that the observed
reduction in 35S-PGs is not caused by a reduction in neither
HS nor CD/DS GAG chain length nor by the number of
GAG chains substituted on the core proteins. However, the
observed decrease in 35S-PGs could be caused by reduced
sulphation of the GAG chains. For this reason, the effect of
GlcN on the polyanionic properties of secreted HSPGs
and CS/DSPGs was investigated using ion-exchange
chromatography, see Fig. 3d. No differences in elution
profiles were observed between samples from control or
GlcN-stimulated cells, suggesting that there were no
differences in the polyanionic properties of neither HSPGs
nor CS/DS PGs after the GlcN treatment compared to
controls. Accordingly, these data show that the decrease in
35S-PGs after GlcN exposure was not due to differences in
polyanionic properties, for example, decreased sulphation.
Taken together, the reduction in 35S-PGs observed as
an effect of GlcN treatment of primary HUVEC was not
caused by a reduction in chain type, length, number or
charge. The data presented suggest that incubating
HUVEC in vitro with GlcN leads to a general decrease
in the expression of the PGs.
Discussion
PGs are important constituents of the extracellular
matrix and are proteins modified with linear GAG
chains. These chains are further modified by sulphate at
distinct positions. Through the GAG chains, PGs have
the ability to bind to partner molecules including matrix
components, chemokines, growth factors and proteases,
and thus, they offer structure as well as protection,
transport and presentation of these molecules. Conse-
quently, the structure of the GAG chains is decisive for
the function of the PG (12).
In this study, we found that HUVEC exposed to
increasing extracellular concentrations of GlcN decreased
the synthesis and secretion of 35S-PGs in a dose- and time-
dependent manner (Fig. 1). We investigated whether the
GlcNAc-containing 35S-HS was more affected than the
GalNAc-containing species 35S-CS/DS. By using cABC,
which specifically degrades CS/DS and HNO2, pH 1.5,
which only degrades HS and heparin, we show that there
was no difference in the effects on these two different 35S-
GAG types when HUVEC were incubated with GlcN
(Fig. 2). Additionally, from Fig. 2, it is evident that the
GAG substitution of HSPG perlecan and CS/DS PG
decorin was not affected by GlcN. From these observa-
tions, we conclude that GlcN exposure does not affect the
ratio between HS and CS/DS.
The reduction in 35S-sulphate incorporation seen in
response to GlcN could be caused by a number of factors.
A reduction in the synthesis of PG core protein, the
number of GAGs attached to each core protein, the GAG
chain length or finally the sulphation of the chains could all
potentially explain this decrease. Studies in arterial smooth
muscle cells show a reduction in PG size caused by reduced
GAG chain length with increasing GlcN concentrations
(13). However, our Sepharose CL-4B data showed that PG
size was not affected by GlcN in HUVEC (Fig. 3a). To
investigate the effect of GlcN on the GAG components,
HS from PGs synthesised in the presence or absence of
GlcN were isolated and separately subjected to chain
length determination by Sepharose CL-6B chromatogra-
phy, with no effect on chain length (Fig. 3b and c). Finally,
no differences in polyanionicity were detected by ion-
exchange chromatography of HS- and CS/DS PGs
(Fig. 3d).
Together, these results show that the observed reduction
in 35S-PGs is explained not by a reduction in HS or CS/DS
ratio, chain length or chain number, nor by a reduction in
the sulphation of the GAGs, but rather by a general
decrease in the total expression of PGs. This is in line with
what we have previously shown for HUVEC exposed to
hyperglycaemic conditions, by incubating the cells in 25 mM
glucose. Under these conditions, we also observed a
decrease in PG expression and secretion (9). The results
presented here show that HUVEC respond to GlcN
exposure in the same manner by decreasing PG synthesis
and secretion.
GAG chains are composed of repeating disaccharide
units of uronic acid and hexosamine. The hexosamine may
be either GlcN in HS and heparin or GalN in CS and DS.
During biosynthesis, GlcN can be converted to UDP-
GlcNAc or UDP-GalNAc, precursors of GAG synthesis.
GlcN is therefore essential for the biosynthesis of PGs (14).
Increased GlcN levels are thought to increase the flux
through the hexosamine biosynthetic pathway; thus,
increased levels of GlcN would be expected to increase
the PG biosynthesis through increased availability of the
substrate for GAG synthesis, the UDP-sugars. Alterna-
tively, increased flux could affect PG levels by changes in
the cytosolic turnover or transport into the Golgi lumen.
However, an inhibition of incorporation of GlcN into
macromolecules has been demonstrated after incubations
with high concentrations of GlcN (15). This was correlated
with a reduction in UDP-GlcNAc caused by ATP deple-
tion by phosphorylation of GlcN into GlcN-6-phosphate
(1618). However, the GlcN concentrations used in those
experiments were as high as 32 mM, and the experiments
were performed in adipocytes and vascular smooth muscle
cells. Also, in the muscle cells, GlcN exposure led to a
decrease in 35S-sulphate incorporation, caused by shorter
GAG chains (13).
Increased flux through the hexosamine pathway could
also affect signalling pathways through O-GlcNAcylation
of signalling proteins or transcription factors (1921).
Such changes may affect the regulation of PG biosynthesis.
O-GlcNAc modifications have been found to be increased
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in the cartilage of patients with knee osteoarthritis,
possibly caused by a proinflammatory milieu (22).
Some studies suggest that GlcN exerts most of its
functions through suppression of inflammatory pathways,
particularly nuclear factor-kB (NF-kB) signalling, and a
decline in proinflammatory cytokines and enzymes (6). In
contrast, others report a GlcN-induced inflammatory
response in HepG2 cells with increased release of proin-
flammatory cytokines and NO together with insulin
resistance (23).
The question whether dietary supplements containing
GlcN or a combination of GlcN and chondroitin are
effective treatments for patients with arthritis is still
controversial (1, 2, 2426). Articular cartilage has very
limited ability to regenerate. The most prominent hypoth-
esis is that PG biosynthesis in chondrocytes is stimulated as
a result of increased GlcN supply, and a lower degradation
of cartilage occurs, which leads to fewer symptoms in, for
example, the knee (2). The availability in chondrocytes of
dietary GlcN supplements has been questioned. Studies on
cells and cartilage tissues have shown that the concentra-
tion of GlcN needed to stimulate PG expression is 10 to
1,000 fold higher than the transient concentration deter-
mined in serum or plasma a few hours after GlcN inges-
tion. Some reports suggest an increased aggrecan core
protein formation (27), inhibition of aggrecan degradation
(28) and reduction in cartilage degradation (29) in cultured
chondrocytes exposed to high concentrations of GlcN
in vitro. The maximum level of GlcN in serum was found to
be in the range of 1.911.5 mM after oral administration
of GlcN (30) or in another study, 4060 mM in plasma (31).
In bovine primary chondrocytes, physiological relevant
concentrations of GlcN did not increase the intracellular
levels of UDP-hexosamine. On the contrary, 1 mM GlcN
seemed to increase the level of UDP-hexosamine, but this
was not accompanied by an increase in 35S-sulphate
incorporation or aggrecan mRNA level (32).
In this study, we have chosen to investigate the effects of
GlcN on primary endothelial cells. In vivo, these cells are
exposed to elevated levels of GlcN after oral intake of
GlcN supplements. This has not been documented for
chondrocytes, where the positive effects of GlcN supple-
ments are assumed to take place. Our results suggest that if,
in endothelial cells, GlcN has any effects on extracellular
matrix constituents, such as PGs, it would be to decrease
the biosynthesis rather than to increase it. However,
whether these results can be extended also to be valid for
chondrocytes is not known at present. Some studies on
GlcN in animal models of arthritis have been performed.
Interestingly, in a rat liver fibrosis model, GlcN decreased
matrix accumulation (33). In another study, an effect of
GlcN on cartilage trough effects on the liver is suggested.
(34). This highlights the necessity to further investigate
what role GlcN plays in other organs that contribute to
inflammation, such as the endothelium. PGs constitute
a diverse group of molecules with several different func-
tions in vascular health and disease, not only as part of
extracellular matrices structurally but also as part of in-
flammation and signal transduction (35). Thus, in en-
dothelium, a reduced PG synthesis could affect endothelial
function in different ways.
Our data do not support the notion that oral intake of
GlcN supplements promotes matrix build-up. The alleged
positive effects of GlcN, if any, could potentially be
because of effects not related to GlcN itself, but rather to
other bioactive components in these products. The pre-
sence of such components could be explained by the high
binding capacity of the negatively charged GAGs and their
degradation products including GlcN.
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